Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy

Mridul Datta, Gary Schwartz

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

An unintended consequence of breast cancer therapies is an increased risk of osteoporosis due to accelerated bone loss. We conducted a systematic review of calcium and/or vitamin D (Ca. ±. D) supplementation trials for maintaining bone mineral density (BMD) in women with breast cancer using the "before-after" data from the Ca. ±. D supplemented comparison group of trials evaluating the effect of drugs such as bisphosphonates on BMD. Whether Ca. ±. D supplements increase BMD in women undergoing breast cancer therapy has never been tested against an unsupplemented control group. However, results from 16 trials indicate that the Ca. ±. D doses tested (500-1500. mg calcium; 200-1000. IU vitamin D) were inadequate to prevent BMD loss in these women. Cardiovascular disease is the main cause of mortality in women with breast cancer. Because calcium supplements may increase cardiovascular disease risk, future trials should evaluate the safety and efficacy of Ca. ±. D supplementation in women undergoing breast cancer therapy.

Original languageEnglish (US)
Pages (from-to)613-624
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume88
Issue number3
DOIs
StatePublished - Jan 1 2013

Fingerprint

Vitamin D
Bone Density
Breast Neoplasms
Calcium
Cardiovascular Diseases
Therapeutics
Diphosphonates
Osteoporosis
Safety
Bone and Bones
Control Groups
Mortality
Pharmaceutical Preparations

Keywords

  • Bone mineral density
  • Breast cancer
  • Calcium
  • Osteoporosis
  • Vitamin D

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy. / Datta, Mridul; Schwartz, Gary.

In: Critical Reviews in Oncology/Hematology, Vol. 88, No. 3, 01.01.2013, p. 613-624.

Research output: Contribution to journalReview article

@article{af1a584946df472bbd84cfb71f35e1d0,
title = "Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy",
abstract = "An unintended consequence of breast cancer therapies is an increased risk of osteoporosis due to accelerated bone loss. We conducted a systematic review of calcium and/or vitamin D (Ca. ±. D) supplementation trials for maintaining bone mineral density (BMD) in women with breast cancer using the {"}before-after{"} data from the Ca. ±. D supplemented comparison group of trials evaluating the effect of drugs such as bisphosphonates on BMD. Whether Ca. ±. D supplements increase BMD in women undergoing breast cancer therapy has never been tested against an unsupplemented control group. However, results from 16 trials indicate that the Ca. ±. D doses tested (500-1500. mg calcium; 200-1000. IU vitamin D) were inadequate to prevent BMD loss in these women. Cardiovascular disease is the main cause of mortality in women with breast cancer. Because calcium supplements may increase cardiovascular disease risk, future trials should evaluate the safety and efficacy of Ca. ±. D supplementation in women undergoing breast cancer therapy.",
keywords = "Bone mineral density, Breast cancer, Calcium, Osteoporosis, Vitamin D",
author = "Mridul Datta and Gary Schwartz",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.critrevonc.2013.07.002",
language = "English (US)",
volume = "88",
pages = "613--624",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy

AU - Datta, Mridul

AU - Schwartz, Gary

PY - 2013/1/1

Y1 - 2013/1/1

N2 - An unintended consequence of breast cancer therapies is an increased risk of osteoporosis due to accelerated bone loss. We conducted a systematic review of calcium and/or vitamin D (Ca. ±. D) supplementation trials for maintaining bone mineral density (BMD) in women with breast cancer using the "before-after" data from the Ca. ±. D supplemented comparison group of trials evaluating the effect of drugs such as bisphosphonates on BMD. Whether Ca. ±. D supplements increase BMD in women undergoing breast cancer therapy has never been tested against an unsupplemented control group. However, results from 16 trials indicate that the Ca. ±. D doses tested (500-1500. mg calcium; 200-1000. IU vitamin D) were inadequate to prevent BMD loss in these women. Cardiovascular disease is the main cause of mortality in women with breast cancer. Because calcium supplements may increase cardiovascular disease risk, future trials should evaluate the safety and efficacy of Ca. ±. D supplementation in women undergoing breast cancer therapy.

AB - An unintended consequence of breast cancer therapies is an increased risk of osteoporosis due to accelerated bone loss. We conducted a systematic review of calcium and/or vitamin D (Ca. ±. D) supplementation trials for maintaining bone mineral density (BMD) in women with breast cancer using the "before-after" data from the Ca. ±. D supplemented comparison group of trials evaluating the effect of drugs such as bisphosphonates on BMD. Whether Ca. ±. D supplements increase BMD in women undergoing breast cancer therapy has never been tested against an unsupplemented control group. However, results from 16 trials indicate that the Ca. ±. D doses tested (500-1500. mg calcium; 200-1000. IU vitamin D) were inadequate to prevent BMD loss in these women. Cardiovascular disease is the main cause of mortality in women with breast cancer. Because calcium supplements may increase cardiovascular disease risk, future trials should evaluate the safety and efficacy of Ca. ±. D supplementation in women undergoing breast cancer therapy.

KW - Bone mineral density

KW - Breast cancer

KW - Calcium

KW - Osteoporosis

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84888286929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888286929&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2013.07.002

DO - 10.1016/j.critrevonc.2013.07.002

M3 - Review article

VL - 88

SP - 613

EP - 624

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -